BOVIE MEDICAL CORPORATION REPORTS RESULTS FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2012 REPORTS ON J-PLASMA ADVANCES

Melville, New York, November 14, 2012 – Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the third quarter and nine months ended September 30, 2012.

Revenues for the third quarter of fiscal 2012 ended September 30, 2012 increased 6.6% to $6.67 million when compared to $6.26 million in the same period last year. Net loss for the third quarter of fiscal 2012 was $(7,000) or $.00 per diluted share versus net income of $63,000 or $.00 per diluted in the third quarter of fiscal 2011.

For the nine months ended September 30, 2012, revenues increased 8.3% to $20.84 million when compared to $19.25 million in the same period last year. Net income for the first nine months of 2012 was $331,000 or $.02 per diluted share versus $984,000 or $.06 per diluted in the first nine months of fiscal 2011, which included the receipt of a one-time payment of $750,000 as part of a legal settlement agreement in the first nine months of fiscal 2011.

Third quarter revenues were positively impacted by increased electrosurgical generator sales both domestically and internationally as well as increased medical lighting sales compared to the previous year. Gross profit margin increased 1.7% during the quarter mainly attributable to increased sales of higher margin products.

In addition to the condensed statement of operations, which are presented in accordance with GAAP, we have included a pro-forma of income from operations for the nine months ended September 30, 2011, which excludes the legal settlement gain from 2011 for comparative purposes.

J-Plasma® Update

The Company continues to make progress with the marketing of J-Plasma®. Training of independent sales representatives covering over half of the United States has been completed with additional representatives having been identified for the remainder of the country.

Bovie attended the 41st AAGL Global Congress on minimally invasive gynecology in Las Vegas, Nevada, November 5th-9th, which is attended annually by over 2,000 gynecologists from throughout the world.

The Company’s participation at the AAGL conference reinforced management’s confidence in J-Plasma’s™ and its belief that it will have a considerable impact on Bovie’s future growth.  At the conference, Bovie contributed to labs specializing in traditional surgical techniques, as well as introducing new surgical techniques. This was the first time Bovie participated in these specialized labs, which are traditionally reserved for much larger medical device companies.

With this additional exposure, Bovie personnel engaged surgeons from around the world as well as from many of the most prestigious teaching hospitals in the United States. The interest expressed by surgeons this year far exceeded that of last year and has resulted in a growing list of qualified leads. The Company will promptly commence evaluations with these surgeons.  Management expects continued successes from these surgical evaluations and anticipates increased sales going into early 2013 and beyond.

J-Plasma® is formed by passing helium over Bovie’s proprietary electrode, which is held at high voltage and high frequency, producing a luminous discharge beam. The electrode is in the form of a retractable surgical blade, providing multiple modes of operation in a single instrument. The extended surgical blade can be used for incisions and other cutting procedures, and when retracted, the blade is used to form the J-Plasma beam for coagulation. The extended blade can also be used in combination with the J-Plasma beam, providing an enhanced cutting capability with minimal impact on surrounding tissue.

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2011.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.

BOVIE MEDICAL CORPORATION
Condensed Statements of Operations For the Three and Nine-Month Periods

(unaudited) (in thousands, except for per share amounts)

Three Months Ended
September 30,
Nine Months Ended
September 30
Nine Months Ended
September 30, 1 Pro Forma
2012
2011
2012
2011
2012
2011
Sales
$6,671
$6,256
$20,843
$19,252
$20,843
$19,252
Cost of Sales
3,777
3,650
12,297
11,167
12,297
11,167
Gross Profit
2,894
2,606
8,546
8,085
8,546
8,085
Gain from settlement litigation
750
Other Costs
2,612
2,358
7,628
7,452
7,628
7,452
Income from operations
282
248
918
1,383
918
633
Other income (expense)
Interest (net of expense)
(58)
(42)
(175)
(141)
Change in fair value of liabilities, net
(135)
(67)
(108)
181
Income before income taxes
89
139
635
1,423
Income Taxes (Provision)
(96)
(76)
(304)
(439)
Net Income (loss)
(7)
63
331
984
EPS Basic
0.00
0.00
0.02
0.06
EPS Diluted
0.00
0.00
0.02
0.06
Weighted average shares Outstanding-Basic
17,634
17,601
17,628
17,592
Weighted average shares adjusted for dilutive securities
17,634
17,774
17,731
17,807

In addition to the condensed statement of operations, which are presented in accordance with GAAP, we have included a pro-forma of income from operations for the nine months ended September 30, 2011, which excludes the legal settlement gain from 2011 for comparative purposes.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com

           BOVIE MEDICAL CORPORATION TO CONDUCT CONFERENCE CALL ON J-Plasma® TECHNOLOGY

Melville, New York, October 23, 2012 – Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced that Jeff Rencher, Vice President of Sales and Marketing of Surgical Products, will host a conference call at 11:00 am EDST on Thursday, November 1st to discuss Bovie’s J-Plasma technology.

Mr. Rencher will be joined on the call by Dr. Royce Adkins, MD, FACOG, an expert in women’s health who is regularly listed as one of “America’s Top Obstetricians and Gynecologist” by Who’s Who’s Best Doctors in America®.” Dr. Adkins is affiliated with Tennessee Women’s Care in Nashville. A board-certified Ob/Gyn, he holds hospital privileges at Baptist Hospital and Centennial Medical Center in Nashville, and he also serves as Clinical Instructor of OB-GYN at Vanderbilt University Medical Center

Shareholders and interested parties may participate in the call by dialing 1 (866) 639-9991 or 1-678-302-3571. Please call a few minutes before the conference call is scheduled to begin. A recording of the live conference call will be immediately available after the call has concluded for the next 30 days. The dial-in number to listen to the recording is 1 (866) 510-4862 or 1-678-302-3562 then enter access code 4804300#. Press 4 to listen and enter the confirmation number 201109205106963#.

Dr. Adkins is an avid researcher, participating as subinvestigator for numerous studies on such topics as hypertension in pregnancy, endometriosis, preterm labor, contraception, vaginal atrophy, osteoporosis, HRT, migraine, bacterial vaginosis, yeast infections, genital herpes, libido disorders, menstural bleeding and hysteroscopic sterilization. He is a frequent speaker at the National ACOG and AAGL annual meetings, having most recently presented on “Evaluating the NovaSure® System for Endometrial Ablation in Patients with a History of C-Section,” and on “Adiana®Hysteroscopic Tubal Occlusion.” He has published on various subjects in Obstetrics and Gynecology. He has also lectured locally and nationally at Universities, hospitals, clinics, and industry-sponsored speakers’ bureaus. Dr. Adkins performed the first office-based NovaSure® procedure in the Southeast, and he is experienced with all types of second-generation endometrial ablation technologies. Dr. Adkins has over 25 years experience with Urogynecology procedures and Pelvic Floor disorders in general. Dr. Adkins and his colleague Dr. Bressman also performed the first Renessa® procedure in Tennessee.

Dr. Adkins is active in AAGL-Advancing Minimally Invasive Gynecology Worldwide and performed the 1st single site laparoscopy at Centennial Medical Center in 2010.

In other news, the Company announced it will be attending and presenting J-Plasma® at the 41st AAGL Global Congress on minimally invasive gynecology November 5-9th in Las Vegas, Nevada. The AAGL conference is attended annually by over 3,000 gynecologists from throughout the world.

 

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2011.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com

           BOVIE MEDICAL ANNOUNCES INITIAL ORDERS FOR J-Plasma®; GRANTED FIFTH PATENT FOR J-Plasma®; PRESENTING AT THE 41ST ANNUAL AAGL CONFERENCE

Melville, New York, October 3, 2012 – Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, today announced that the Company has received initial orders for J-Plasma® and has been granted its fifth patent for the product. The Company has five additional patents pending based on the J-Plasma® technology.

In other news, the Company will be attending and presenting J-Plasma® at the 41st AAGL Global Congress on minimally invasive gynecology November 5-9th in Las Vegas, Nevada. The AAGL conference is attended annually by over 3,000 gynecologists from throughout the world.

J-Plasma®

J-Plasma® is formed by passing helium over Bovie’s proprietary electrode, which is held at high voltage and high frequency, producing a luminous discharge beam. The electrode can also be in the form of a retractable surgical blade, providing multiple modes of operation in a single instrument. The extended surgical blade can be used for incisions and other cutting procedures, and when retracted, the blade is used to form the J-Plasma beam for coagulation. The extended blade can also be used in combination with the J-Plasma beam, providing an enhanced cutting capability with minimal impact on surrounding tissue.

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2011.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com

           BOVIE MEDICAL TO PRESENT AT THE 2012 SEETHRUEQUITY FALL SMALLCAP AND MICROCAP CONFERENCE ON TUESDAY, OCTOBER 2ND

Melville, New York, October 1, 2012 – Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products and its new J-Plasma® system, today announced that the Company will present at the 2012 SeeThru Equity Fall Smallcap and Microcap Conference Tuesday, October 2, 2012 at 11:20am ET, at The Cornell Club 6 East 44th Street New York City, New York.

Investors will be able to access a replay of the presentation within 24 hours on the Company’s website www.boviemed.com or SeeThruEquity’s website www.seethruequity.com for the next 90 days.

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2011.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com

BOVIE MEDICAL CORPORATION REPORTS RESULTS FOR THREE AND SIX-MONTHS ENDED JUNE 30, 2012: J-Plasma® ACHIEVES KEY MILESTONES

Melville, New York, August 14, 2012 – Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the second quarter and six months ended June 30, 2012.

For the second quarter of fiscal 2012, ended June 30, 2012, revenues increased 8.8% to $7.44 million when compared to $6.84 million in the same period last year. Net income for the second quarter of fiscal 2012 was $152,000 or $.01 per diluted share versus $429,000 or $.02 per diluted in the second quarter of fiscal 2011.

For the six months ended June 30, 2012 revenues increased 9.1% to $14.17 million when compared to $12.99 million in the same period last year; resulting in a net income of $339,000 or $.02 per diluted share, versus $921,000 or $.05 per diluted in the first six months of fiscal 2011.  The Company received a payment of $750,000 as part of a legal settlement agreement in the first six months of fiscal 2011.

In addition to the condensed statement of operations, which are presented in accordance with GAAP, we have included a pro-forma of income from operations for the six months ended June 30, 2011, which excludes the legal settlement gain from 2011 for comparative purposes.

J-Plasma® Update

Since last reporting on J-Plasma®, significant progress continues to be made. Jeff Rencher, Vice President of Sales and Marketing of Surgical Products stated, “Since introducing J-Plasma® to surgeons approximately six weeks ago we have achieved three significant milestones.  First and most importantly, the product performed as intended and each surgical procedure was completed successfully.  Secondly, when compared to similar devices, we have proven the viability and superior performance of our device and technology in the targeted specialties of GYN, plastics and general surgery.  Thirdly, we have gained acceptance from both surgeons who were familiar with plasma and those who were only recently introduced to the technology through Bovie’s J-Plasma®.  To date, we have completed 21 cases including: hysterectomies, adhesiolysis, hernia, breast augmentation and endometriosis, in which surgeons utilized J-Plasma® on human patients in an operating room setting.  Bovie remains focused on the GYN market with surgeons who have used the product indicating a clear preference for J-Plasma® in lieu of those devices they previously used.  As the Company further expands its market presence throughout the U.S., we will continue our evaluations in new areas of surgery and anticipate continued acceptance in future cases.  Additionally, the product continues to be used successfully by veterinary surgeons in a variety of applications.”

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2011.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.

BOVIE MEDICAL CORPORATION
Condensed Statements of Operations For the Three and Six-Month Periods

(unaudited) (in thousands, except for per share amounts)

Three Months Ended
June 3
Six Month Ended
June 30
Six Month Ended
June 30, Pro Forma 1
2012
2011
2012
2011
2012
2011
Sales
$7,440
$6,841
$14,173
$12,995
$14,173
$12,995
Cost of Sales
4,584
3,796
8,521
7,517
8,521
7,517
Gross Profit
2,856
3,045
5,652
5,478
5,652
5,478
Gain from settlement litigation
750
Other Costs
2,616
2,496
5,016
5,093
5,016
5,093
Income from operations
240
549
636
1,135
636
385
Other income (expense)
Interest (net of expense)
(58)
(46
(116)
(98)
Change in fair value of liabilities, net
44
107
27
248
Income before income taxes
226
610
547
1,285
Income Taxes (Provision)
(74)
(181)
(208)
(364)
Net Income (loss)
$152
$429
$339
$921
EPS Basic
0.01
0.02
0.02
0.05
EPS Diluted
0.01
0.02
0.02
0.05
Weighted average shares Outstanding-Basic
17,629
17,600
17,625
17,769
Weighted average shares adjusted for dilutive securities
17,768
17,827
17,769
17,829

In addition to the condensed statement of operations, which are presented in accordance with GAAP, we have included a pro-forma of income from operations for the six months ended June 30, 2011, which excludes the legal settlement gain from 2011 for comparative purposes.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com

           BOVIE MEDICAL CORPORATION REPORTS POSITIVE RESULTS ON J-Plasma®

Melville, New York, July 10, 2012 – Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, today announced that J-Plasma® is performing well in both laparoscopic and open surgeries.  In multiple patient procedures there was a decrease in smoke, less charring and overall excellent tissue response when compared to current electrosurgery devices.  Jeff Rencher, Vice President of Sales and Marketing of Surgical Products stated, “The positive results achieved by J-Plasma® met all expectations as we prepare to embark on an aggressive marketing program for the product.”

He added, “We will continue to introduce J-Plasma® in a limited format over the next two weeks; however, with the early success of the product in human cases and the continued success and extensive use in live veterinarian cases, we will be moving into expanded markets during the current quarter.  Gynecology and Plastic Surgery will continue to be the main focus for J-Plasma®.  Additionally, we expect to be performing ENT and General Surgery procedures as the technology establishes itself as a viable alternative to traditional and competitive devices.”

In unrelated news, the Company reported that it’s previously announced anticipated developmental and manufacturing agreement with a large multi-national medical device company remains in the due-diligence and negotiation stage.

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2011.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com

           BOVIE MEDICAL CORPORATION REPORTS 9.4 PERCENT INCREASE IN FIRST QUARTER REVENUES; REPORTS POSITIVE RESULTS IN J-Plasma® SURGERIES

Melville, New York, May 15, 2012 – Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2012.

For the first quarter of fiscal 2012, ended March 31, 2012 revenues increased 9.4% to $6.73 million when compared to $6.15 in the same period last year. Net income for the current year first quarter was $321,000 or $.01 per diluted share versus $674,000 or $.03 per diluted in the first three months of fiscal 2011.

In addition to the condensed statement of operations in accordance with GAAP, we have included a pro-forma of income (loss) from operations, which excludes the one-time legal settlement gain from the first quarter of 2011.  This resulted in our pro-forma income (loss) from operations improving by approximately $561,000 over the prior period.

During the first three months of 2012, Bovie experienced increases in sales across all product lines and this trend has continued into the second quarter.

J-Plasma®

Jeff Rencher, Vice President of Sales and Marketing of Surgical Products, spearheading the launch of J-Plasma®, commented, “As Bovie prepares the near term delivery of J-Plasma® units to university/hospital beta sites, we are both assured and encouraged by its performance as reported by Matt G. Oakes, DVM, Diplomat, American College of Veterinary Surgeons, Tampa Bay Veterinary Specialists.”

Dr. Oakes stated, “Tampa Bay Veterinary Surgery has been excited to try out the new technology behind the J-Plasma® unit brought to us by Bovie.  We have found the cutting mode with the extended blade to work extremely well for skin incisions in dogs.  The skin cuts with no resistance, no visible incisional edge char, and minimal smoke or odor.  Recheck of our initial cases at 2 weeks showed excellent healing without crusting of the incision line that is typical of those incised with traditional electrocautery.  The J-Plasma® beam is useful for coagulation of small vessels and we are continuing to try varied settings to optimize this function.  We are looking forward to trying J-Plasma® for other applications such as oral and soft palate surgery, liver hemostasis, and tumor bed treatment.”

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2011.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com

BOVIE MEDICAL CORPORATION ANNOUNCES 2011 YEAR END FINANCIAL RESULTS AND REPORTS ON J-Plasma® PROGRESS

Melville, New York, March 29, 2012- Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the fourth quarter and year ended December 31, 2011.

Revenues for the year ended December 31, 2011 increased 4.9% to $25.4 million versus $24.2 million for the comparable period the prior year. Net income for FY 2011 totaled $109,000 or $.01 per diluted share compared to a net loss of $(1,535,000) or $(.09) per share in the same period last year. Higher sales resulted from increased demand for Bovie’s electrosurgical generators both domestically and internationally. Newly introduced product lines in medical lighting systems and coated blades also contributed to the revenue increase.

In addition to the condensed statement of operations in accordance with GAAP, we have included a pro-forma of income (loss) from operations excluding the effect of legal settlements in 2011 and the asset impairment in 2010, income (loss) from operations improved to approximately $823,000 and $(1,466,000) in 2011 and 2010 respectively.

Revenues for the quarter ended December 31, 2011 were $6.1 million versus $6.2 million in the same period last year; resulting in net loss of $(876,000) or $(.05) per diluted share compared to net loss of $(1,369,000) or $(.08) per share in the same period last year. In the fourth quarter of fiscal 2011, the Company recognized a $1,591,000 expense for the transfer of inventory and intellectual property related to a legal settlement.

In other developments, the Company announced today that it has signed several interim and related product development agreements with a major multi-national medical device company in anticipation of a final developmental and manufacturing agreement expected to be completed in the second quarter this year.

The Company’s current balance sheet remains strong and management is encouraged by increased first quarter sales, which point to positive sales momentum.  Additionally, progress continues on J-Plasma® following the previously announced FDA 510K clearance to market.

Jeff Rencher, Vice President of Sales and Marketing of Surgical Products heading up the marketing of J-Plasma® commented that, “After recently presenting J-Plasma® at the World Robotic Gynecological Congress and the International Society for Gynecologic Endoscopy, we are even more confident in the technology’s potential. The interest demonstrated by surgeons at these trade shows indicates a need for J-Plasma® and a desire to implement the product in the gynecological surgery space.  We will continue to introduce surgeons to J-Plasma®, and Bovie Medical in general, at trade shows throughout the year.

Our plan is to deliver the product in the coming weeks to select surgeons that range from world renowned surgical instructors to surgeons with previous experience in inert gas plasmas, then shortly after offering it to the U.S. surgical marketplace. Although Gynecology is our initial focus, we expect to target additional medical procedures in the General, Plastics and Urology markets as well.”

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2011.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.

BOVIE MEDICAL CORPORATION
Condensed Statements of Operations For the Three and twelve-month Periods

(in thousands, except for per share amounts)

Three Months Ended
December 31 (Unaudited)
Year Ended
December 31
Year Ended
December 31, Pro Forma 1
2011
2010
2011
2010
2011
2010
Revenues
$6,159
$6,233
$25,411
$24,230
$25,411
$24,230
Cost of Sales
3,513
3,550
14,680
14,242
14,680
14,242
Gross Profit
2,646
2,683
10,731
9,988
10,731
9,988
Gain (loss) on legal settlement
750
Costs & Expenses
2,457
2,911
9,908
11,454
9,908
11,454
Legal Settlement
1,591
1,591
Asset Impairment
1,286
1,286
Income (loss) from operations
(1,402)
(1,514)
(18)
(2,752)
823
(1,466)
Other income (expense)
Interest (net of expense)
(96)
(54)
(237)
(223)
(237)
(223)
Other Gain (loss)
106
(285)
287
513
287
513
Income (loss) before income taxes
(1,392)
(1,853)
32
(2,462)
$873
$(1,176)
Income Taxes (Provision) Benefit
516
484
77
927
Net Income (loss)
$(876)
$(1,369)
$109
$(1,535)
EPS (loss) Basic
(0.05)
(.08)
0.01
(0.09)
EPS (loss) Diluted
(0.05)
(.08)
0.01
(0.09)
Weighted average shares Outstanding-Basic
17,614
17,561
17,597
17,367
Weighted average shares adjusted for dilutive securities
17,614
17,561
17,669
17,367

In addition to the condensed statement of operations in accordance with GAAP, we have included a pro-forma1 of income (loss) from operations excluding the effect of legal settlements in 2011 and the asset impairment in 2010, income (loss) from operations improved to approximately $823,000 and $(1,466,000) in 2011 and 2010 respectively.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com

           BOVIE MEDICAL CORPORATION RECEIVES 510 K CLEARANCES TO MARKET PATENTED J-Plasma® TECHNOLOGY

Melville, New York, February 1, 2012 – Bovie Medical Corporation (“Bovie” or the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced that the Company received 510k clearance from the Food and Drug Administration (FDA) to market its J-Plasma® handpiece with retractable cutting feature for soft tissue coagulation during surgery. The handpiece will be powered by Bovie’s GS electrosurgical generator, which has prior 510k market clearance.

J-Plasma® is formed by passing an inert gas, such as helium, over a sharp conductive point which is held at high voltage and high frequency, producing a luminous discharge beam. The sharp conductive point can also be in the form of a retractable surgical blade, providing multiple modes of operation in a single instrument. The extended surgical blade can be used for incisions and other cutting procedures, and when retracted, the blade is used to form the J-Plasma beam for coagulation. The extended blade can also be used in combination with the J-Plasma beam, providing an enhanced cutting capability with minimal impact on surrounding tissue.

The Company, assisted by leading surgeons, will introduce J-Plasma® at selected hospital beta sites including several university teaching facilities, in preparation for a market launch later this year by its independent sales distribution network.

Bovie continues to explore and review added applications for J-Plasma® which include gynecology, dermatology, plastic surgery, infection control, use in robotics and other surgical techniques.

Bovie Medical Corporation CEO Andrew Makrides commented, “This is a significant development toward Bovie becoming a leader in plasma surgery and achieving increased prominence in the electrosurgery marketplace.”

Bovie recently announced the granting of a United States patent for a “Method to generate a plasma stream for performing electrosurgery”, adding to the Company’s J-Plasma® patent portfolio. Bovie has four patents related to its J-Plasma® technology with three additional patent applications pending.

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the Company’s ability to control or predict.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10‑K for the year ended December 31, 2010.  For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.

Contact Information
Bovie Medical Investor Relations and Shareholder Information:
investor.relations@boviemed.com